Profile data is unavailable for this security.
About the company
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
- Revenue in USD (TTM)40.36m
- Net income in USD-375.84m
- Incorporated2022
- Employees30.00
- LocationScilex Holding Co960 San Antonio RoadPALO ALTO 94303United StatesUSA
- Phone+1 (650) 516-4310
- Fax+1 (302) 636-5454
- Websitehttps://www.scilexholding.com/
More ▼
Mergers & acquisitions
| Acquired company | SCLX:NAQ since announced | Transaction value |
|---|---|---|
| Datavault AI Inc | -70.93% | 150.00m |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Odonate Inc | 0.00 | -102.07m | 52.65m | 137.00 | -- | 2,022.38 | -- | -- | -108.70 | -108.70 | 0.00 | 74.17 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Janel Corp | 207.44m | 5.03m | 56.94m | 353.00 | 11.50 | 2.21 | 6.62 | 0.2745 | 4.18 | 4.18 | 172.09 | 21.75 | 1.47 | 32.80 | 4.14 | 587,657.30 | 4.02 | 1.76 | 13.35 | 5.33 | 31.33 | 26.69 | 2.73 | 0.9608 | 0.7013 | 3.10 | 0.3913 | 0.00 | 13.24 | 20.27 | 2,155.61 | -- | -14.58 | -- |
| Cumberland Pharmaceuticals, Inc. | 41.28m | -3.33m | 58.03m | 91.00 | -- | 2.22 | 45.99 | 1.41 | -0.2331 | -0.2331 | 2.79 | 1.75 | 0.5788 | 1.72 | 3.80 | 453,608.30 | -4.68 | -6.88 | -7.60 | -9.65 | 84.49 | 80.74 | -8.09 | -15.89 | 1.11 | -28.41 | 0.1688 | -- | -4.26 | 1.95 | -3.19 | -- | -29.32 | -- |
| ImmuCell Corp | 27.77m | 2.32m | 59.70m | 70.00 | 25.51 | 2.00 | 11.89 | 2.15 | 0.2588 | 0.2588 | 3.09 | 3.29 | 0.6159 | 1.90 | 11.42 | 402,453.60 | 5.15 | -5.35 | 5.69 | -5.77 | 40.93 | 36.02 | 8.37 | -11.87 | 1.76 | 6.47 | 0.2415 | -- | 51.64 | 14.06 | 62.65 | -- | -19.66 | -- |
| Rafael Holdings Inc | 1.03m | -31.33m | 62.12m | 21.00 | -- | 0.738 | -- | 60.36 | -0.8471 | -0.8471 | 0.0284 | 1.63 | 0.0107 | -- | 3.35 | 49,000.00 | -32.33 | -45.03 | -37.62 | -51.75 | 89.70 | -- | -3,034.89 | -8,772.74 | 3.98 | -- | 0.0074 | -- | 43.96 | -28.51 | 11.30 | -- | -47.65 | -- |
| LifeVantage Corp | 210.05m | 7.86m | 64.35m | 232.00 | 8.39 | 1.95 | 5.97 | 0.3064 | 0.5998 | 0.5998 | 16.16 | 2.58 | 3.24 | 2.45 | 96.73 | 905,370.70 | 12.12 | 9.17 | 18.91 | 14.08 | 78.75 | 80.73 | 3.74 | 2.93 | 1.03 | -- | 0.00 | 35.06 | 14.17 | -0.3794 | 233.84 | -3.22 | -12.55 | -- |
| MindWalk Holdings Corp | 14.98m | -22.73m | 64.82m | 102.00 | -- | 4.93 | -- | 4.33 | -0.6315 | -0.6132 | 0.3511 | 0.2813 | 0.4745 | 6.67 | 4.50 | -- | -72.01 | -32.32 | -90.53 | -36.45 | 58.50 | 55.79 | -151.78 | -100.97 | 4.09 | -23.68 | 0.17 | -- | 0.0082 | 11.77 | -11.25 | -- | 10.37 | -- |
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 66.58m | 4.00 | -- | 1.09 | -- | 8.99 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 68.21m | 171.00 | -- | 0.3405 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| NovaBay Pharmaceuticals Inc | 2.83m | -7.95m | 68.45m | 14.00 | -- | -- | -- | 24.19 | -1.58 | 0.5377 | 0.555 | 0.2718 | 0.7686 | -- | 5.28 | 202,142.90 | -215.92 | -61.58 | -404.37 | -83.79 | 54.56 | 59.49 | -280.92 | -77.39 | -- | -91.56 | 0.0836 | -- | -33.58 | 8.19 | 48.52 | -- | -20.59 | -- |
| Nasus Pharma Ltd | 0.00 | -1.19m | 69.08m | -- | -- | -- | -- | -- | -0.1319 | -0.1383 | 0.00 | -0.4762 | 0.00 | -- | -- | -- | -373.32 | -- | -- | -- | -- | -- | -- | -- | -- | -2.51 | -- | -- | -- | -- | -54.23 | -- | -- | -- |
| Scilex Holding Co | 40.36m | -375.84m | 70.56m | 30.00 | -- | -- | -- | 1.75 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Assertio Holdings Inc | 137.35m | -28.92m | 79.41m | 58.00 | -- | 0.7505 | 35.98 | 0.5781 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Polypid Ltd | 0.00 | -34.17m | 80.64m | 57.00 | -- | 7.35 | -- | -- | -2.26 | -2.26 | 0.00 | 0.6028 | 0.00 | -- | -- | -- | -143.79 | -105.84 | -252.10 | -143.44 | -- | -- | -- | -- | 1.82 | -27.54 | 0.0826 | -- | -- | -- | -17.73 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Scilex Holding Co's reporting currency: US Dollar USD
7.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 252.43k | 2.97% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 97.26k | 1.15% |
| Armistice Capital LLCas of 30 Sep 2025 | 66.00k | 0.78% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 39.66k | 0.47% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 38.46k | 0.45% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 34.35k | 0.41% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 19.85k | 0.23% |
| Ashton Thomas Private Wealth LLCas of 31 Dec 2025 | 17.99k | 0.21% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 15.16k | 0.18% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 13.57k | 0.16% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
